As 2025 approaches, significant changes are on the horizon for Prescription Drug Plans (PDPs), largely driven by the Inflation Reduction Act (IRA). These changes include the elimination of the Coverage Gap (or “donut hole”), a new $2,000 out-of-pocket spending cap, and adjustments in cost-sharing responsibilities during the catastrophic coverage phase.
In light of these shifts, Wellcare has made the difficult decision to cease new and renewal commissions for their PDP products starting January 1, 2025. Meanwhile, Aetna’s SilverScript Choice PDP will be offered as a non-commissionable product nationwide, with renewal commissions continuing on existing commissionable business.
Stay informed and prepared as these updates will impact your approach to PDP offerings in the upcoming year.